Biological Factors

Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity

23 hours ago talkbio0Tagged Biological Factors, Boost, Capacity, CDMO, Fujifilm, Manufacture, Regeneron, United States

Regeneron, Manufacture, Fujifilm, CDMO, Biological Factors, Capacity, United States, Boost

Trump pledges his support for a change to the IRA long sought by drugmakers

1 week ago talkbio0Tagged Biological Factors, Contraceptives, Oral, drug price, drugmakers, Industry, IRA, Mediation, Medicare, Prices

IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

1 week ago talkbio0Tagged amgen, Approved, Biological Factors, Biosimilars, competition, Enbrel, Erelzi, etanercept, Legal patent, Market, Rheumatoid Arthritis, sandoz, United States, United States Food and Drug Administration

Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.

Amgen Secures Phase 3 Survival Data for Imdelltra in Small-Cell Lung Cancer, Strengthening Its Case for Full FDA Approval

1 week ago talkbio0Tagged amgen, Biological Factors, DLL3-targeting therapy, Imdelltra, Immunotherapy, Overall Survival, Phase 3 trial, SCLC, small-cell lung cancer

Imdelltra, Amgen, Small-cell lung cancer (SCLC), Phase 3 trial, Overall survival, DLL3-targeting therapy, Immunotherapy, Biopharmaceuticals

Novartis to invest $23B in manufacturing so ‘all key medicines’ can be made in the US

2 weeks ago talkbio0Tagged Biological Factors, Investments, Manufacture, Novartis, production, United States

Novartis, United States, Investments, Manufacture, production, Biological Factors, Novartis

Chiesi unveils 430M investment to revitalize Italian production site for inhaler, biologics manufacturing

4 weeks ago talkbio0Tagged Biological Factors, Inhaler, Investments, production

Investments, Inhaler, Biological Factors, production

Lonza’s Vision for the Future: A Fireside Chat with New CEO Wolfgang Wienand

1 month ago talkbio0Tagged Biological Factors, CDMO, Cells, gene therapy, Industry, Leadership, Lonza, pharmaceutical manufacturing, Small Molecule, Wolfgang Wienand

Lonza, Wolfgang Wienand, CDMO, Pharmaceutical manufacturing, Biologics, Cell and gene therapy, Small molecules, Leadership transition, Industry outlook

Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger

2 months ago talkbio0Tagged Acelyrin, Acquisition, all-stock, Alumis, Biological Factors, Concentra Biosciences, Immunology, Merger, Transaction

Acelyrin, Concentra Biosciences, Alumis, Merger, Acquisition offer, Immunology, Biopharmaceuticals, All-stock transaction

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

3 months ago talkbio0Tagged Arenaria, Biological Factors, clinical program, Discontinuation (procedure), Financial cost, Industry, Lymphocytes, Tumor-Infiltrating, Manufacturing, strategic alternatives, TIDAL-01

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges

Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

3 months ago talkbio0Tagged Biological Factors, Biopharma, CDMO, Cells, Demand (clinical), gene therapy, Manufacturing, Market, Rentschler, Stevenage facility closure, strategic realignment

Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure